Actym Therapeutics Raises $34 Million Series A
04/27/20, 12:43 PM
Location
berkeleyMoney raised
$34 million
Round Type
series a
Actym Therapeutics, a privately-held immuno-oncology company, announced today the completion of a $34 million series A financing led by Boehringer Ingelheim Venture Fund (BIVF) and Panacea Venture, with participation from Illumina Ventures, Korea Investment Partners (KIP), and JLo Ventures. The company will use the proceeds to advance development of immunotherapies from its microbial-based STACT platform into the clinic for the treatment of various cancers. Actym is led by industry veterans Christopher Thanos, Ph.D., Chief Executive Officer, Laura Hix Glickman, Ph.D., Vice President Research, and Mark Frohlich, M.D., Chief Medical Advisor.
Company Info
Company
Actym
Location
berkeley, california, united states
Additional Info
Actym Therapeutics is based in Berkeley, California and was founded in 2017 by Christopher Thanos Ph.D., Laura Hix Glickman, Ph.D., and Amit Kumar, Ph.D. The company has developed a microbial-based immunotherapy platform called STACT (S. Typhimurium Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payloads are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after IV dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy.